GRACE :: Lung Cancer

Search cancerGRACE.org

Dr West

Are There Significant Differences Among EGFR Mutations?

Share
download as a pdf file Download PDF of this page

Since we’ve come to appreciate the presence of distinct activating EGFR mutations associated with a very high probability of responding to an oral EGFR inhibitor, the question has emerged about whether there are significant differences in outcomes between the two most common ones, which are a deletion in exon 19 and a “point mutation” in exon 21. Some retrospective work in smaller aggregated series has suggested that patients with an exon 19 deletion tend to do best, but other work has suggested no difference between these two most common mutations. The recently reported trio of prospective trials of patients with an EGFR mutation receiving first line chemo or an EGFR inhibitor provide a good opportunity to evaluate this question.

The studies are actually pretty consistent in conveying that there is a modest trend toward the most favorable progression-free survival (PFS) in people with an exon 19 vs. an exon 21 mutation, but the differences aren’t great. Here are the PFS curves directly comparing the two main types of mutations in the Japanese trials with Iressa (gefitinib):

pfs-by-type-of-egfr-mutation (Click on image to enlarge)

So while the curve for exon 19 deletion is on top by a small margin, both activating mutations appear to follow a very similar trajectory overall, with no significant difference.

The Chinese OPTIMAL trial of standard chemotherapy vs. Tarceva (erlotinib) in patients with an EGFR mutation also presented results for PFS by EGFR mutation subtype, though the presentation included separate curves for each mutation compared to the standard chemotherapy arm:

optimal-pfs-by-type-of-egfr-mutation Here, again, there is a very striking, clinically significant difference in PFS favoring Tarceva for both groups (don’t be put off by the fact that the differences aren’t statistically significant in these two trials, since the power to do so is very reduced in subgroups half the size of the main trial). Though the difference is a little greater with an exon 19 deletion vs. an exon 21 mutation, with a median PFS 15.3 and 12.5 months respectively, the general principles hold up, and clearly both major EGFR mutation subtypes show the same effect of clear benefit for EGFR inhibitor therapy.

Practically speaking, there may be a tendency toward the most favorable results in patients with an exon 19 deletion, but clearly the patients with an activating EGFR mutation in exon 21 also show the same profound PFS benefit with an EGFR inhibitor compared with standard chemo, so I don’t think there’s any practical distinction to be made. We can say that with increasing confidence as we do more studies that specifically focus on populations of patients with an EGFR mutation.


5 Responses to Are There Significant Differences Among EGFR Mutations?

  • kej says:

    Interesting – again :-)
    Next thing is to know how much time it buys when adding a drug to overcome Tarceva/Iressa resistance. Are there any early results in that respect?

  • Dr West
    Dr West says:

    No, those trials are just getting going. That’s a question for the next few years.

  • Laya D. says:

    Wonderful! Thanks Dr. West. . .

    Laya

  • tarora says:

    Dr West,
    My wife has lung cancer. She has been assessed to have EGFR wild type. What is that and which drug would be appropriate once progression sets in ( She is right now stable with Avastin since July 2010) ? She also has KRAS mutation.
    Thanks
    toarora

  • Dr West
    Dr West says:

    Here is a summary of the leading treatment options for second line treatments of advanced NSCLC, following progression:

    http://cancergrace.org/lung/2010/10/04/lung-cancer-faq-2nd-line-nsclc-option/

    In addition, here is a discussion of the work supporting the concept that patients who do not have an EGFR mutation can still receive a clinically meaningful benefit from an EGFR inhibitor:

    http://cancergrace.org/lung/2010/09/21/benefit-from-egfr-tki-if-egfr-wt/

    The limited data on patients with a KRAS mutation suggests that these people are especially unlikely to have a dramatic benefit from an oral EGFR inhibitor, but they can still have a modest improvement in terms of prolonged stable disease or even minor tumor shrinkage, delay in progression-free survival, and prolonged survival that is comparable to what you’d see with conventional chemotherapy.

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243